Last reviewed · How we verify
VYD2311-SD
VYD2311-SD is a COVID-19 vaccine.
VYD2311-SD is a COVID-19 vaccine. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
At a glance
| Generic name | VYD2311-SD |
|---|---|
| Sponsor | Invivyd, Inc. |
| Drug class | vaccine |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating an immune response against the SARS-CoV-2 virus. This vaccine is designed to provide protection against COVID-19 by inducing the production of antibodies and immune cells that can recognize and fight the virus.
Approved indications
- Prevention of COVID-19 disease caused by SARS-CoV-2 virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VYD2311-SD CI brief — competitive landscape report
- VYD2311-SD updates RSS · CI watch RSS
- Invivyd, Inc. portfolio CI